Resultats de la cerca - Natarajan Muthusamy

Refinar resultats
  1. 1
    Tetraspanins as therapeutic targets in hematological malignancy: a concise review

    Tetraspanins as therapeutic targets in hematological malignancy: a concise review per Kyle A. Beckwith, John C. Byrd, Natarajan Muthusamy

    Publicat 2015
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  2. 2
    The clinical application of monoclonal antibodies in chronic lymphocytic leukemia

    The clinical application of monoclonal antibodies in chronic lymphocytic leukemia per Samantha Jaglowski, Lapo Alinari, Rosa Lapalombella, Natarajan Muthusamy, John C. Byrd

    Publicat 2010
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  3. 3
    The Ets-1 Transcription Factor Is Required for the Development of Natural Killer Cells in Mice

    The Ets-1 Transcription Factor Is Required for the Development of Natural Killer Cells in Mice per Kevin Barton, Natarajan Muthusamy, Christopher Fischer, Chao-Nan Ting, Theresa L. Walunas, Lewis L. Lanier, Jeffrey M. Leiden

    Publicat 1998
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  4. 4
    Human T-Cell Lymphotropic Virus Type 1 p12<sup>I</sup>Expression Increases Cytoplasmic Calcium To Enhance the Activation of Nuclear Factor of Activated T Cells

    Human T-Cell Lymphotropic Virus Type 1 p12<sup>I</sup>Expression Increases Cytoplasmic Calcium To Enhance the Activation of Nuclear Factor of Activated T Cells per Wei Ding, Björn Albrecht, Robert E. Kelley, Natarajan Muthusamy, Seung-Jae Kim, Ruth A. Altschuld, Michael D. Lairmore

    Publicat 2002
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  5. 5
    A Phase I Dose-Finding Trial of Recombinant Interleukin-21 and Rituximab in Relapsed and Refractory Low Grade B-cell Lymphoproliferative Disorders

    A Phase I Dose-Finding Trial of Recombinant Interleukin-21 and Rituximab in Relapsed and Refractory Low Grade B-cell Lymphoproliferative Disorders per John M. Timmerman, John C. Byrd, David Andorsky, Reiko Yamada, Janet Kramer, Natarajan Muthusamy, Naomi Hunder, John M. Pagel

    Publicat 2012
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  6. 6
    Dual-targeting immunotherapy of lymphoma: potent cytotoxicity of anti-CD20/CD74 bispecific antibodies in mantle cell and other lymphomas

    Dual-targeting immunotherapy of lymphoma: potent cytotoxicity of anti-CD20/CD74 bispecific antibodies in mantle cell and other lymphomas per Pankaj Gupta, David M. Goldenberg, Edmund A. Rossi, Thomas M. Cardillo, John C. Byrd, Natarajan Muthusamy, Richard R. Furman, Chien‐Hsing Chang

    Publicat 2012
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  7. 7
    Comparative Assessment of Clinically Utilized CD20-Directed Antibodies in Chronic Lymphocytic Leukemia Cells Reveals Divergent NK Cell, Monocyte, and Macrophage Properties

    Comparative Assessment of Clinically Utilized CD20-Directed Antibodies in Chronic Lymphocytic Leukemia Cells Reveals Divergent NK Cell, Monocyte, and Macrophage Properties per Sarwish Rafiq, Jonathan P. Butchar, Carolyn Cheney, Xiaokui Mo, Rossana Trotta, Michael A. Caligiuri, David Jarjoura, Susheela Tridandapani, Natarajan Muthusamy, John C. Byrd

    Publicat 2013
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  8. 8
    Characterization of the TCL-1 transgenic mouse as a preclinical drug development tool for human chronic lymphocytic leukemia

    Characterization of the TCL-1 transgenic mouse as a preclinical drug development tool for human chronic lymphocytic leukemia per Amy J. Johnson, David Lucas, Natarajan Muthusamy, Lisa L. Smith, Ryan B. Edwards, Michael De Lay, Carlo M. Croce, Michael R. Grever, John C. Byrd

    Publicat 2006
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  9. 9
    Therapeutic CD94/NKG2A blockade improves natural killer cell dysfunction in chronic lymphocytic leukemia

    Therapeutic CD94/NKG2A blockade improves natural killer cell dysfunction in chronic lymphocytic leukemia per Emily M. McWilliams, Jennifer M. Mele, Carolyn Cheney, Elizabeth A. Timmerman, Faraz Fiazuddin, Ethan Strattan, Xiaokui Mo, John C. Byrd, Natarajan Muthusamy, Farrukh T. Awan

    Publicat 2016
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  10. 10
    FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma

    FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma per Qing Liu, Xiaobin Zhao, Frank Frissora, Yihui Ma, Ramasamy Santhanam, David Jarjoura, Amy Lehman, Danilo Perrotti, Ching‐Shih Chen, James T. Dalton, Natarajan Muthusamy, John C. Byrd

    Publicat 2007
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  11. 11
    Ets1 and Ets2 are required for endothelial cell survival during embryonic angiogenesis

    Ets1 and Ets2 are required for endothelial cell survival during embryonic angiogenesis per Wei Guo, Ruchika Srinivasan, Carmen Z. Cantemir-Stone, Sudarshana M. Sharma, Ramasamy Santhanam, Michael Weinstein, Natarajan Muthusamy, Albert K. Man, Robert G. Oshima, Gustavo Leone, Michael C. Ostrowski

    Publicat 2009
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  12. 12
    Chronic Lymphocytic Leukemia–Derived IL-10 Suppresses Antitumor Immunity

    Chronic Lymphocytic Leukemia–Derived IL-10 Suppresses Antitumor Immunity per Sara S. Alhakeem, Mary K. McKenna, Karine Z. Oben, Sunil K. Noothi, Jacqueline R. Rivas, Gerhard C. Hildebrandt, Roger A. Fleischman, Vivek M. Rangnekar, Natarajan Muthusamy, Subbarao Bondada

    Publicat 2018
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  13. 13
    PI3K p110δ inactivation antagonizes chronic lymphocytic leukemia and reverses T cell immune suppression

    PI3K p110δ inactivation antagonizes chronic lymphocytic leukemia and reverses T cell immune suppression per Shuai Dong, Bonnie K. Harrington, Eileen Hu, J.T. Greene, Amy M. Lehman, Minh Tran, Ronni Wasmuth, Meixiao Long, Natarajan Muthusamy, Jennifer R. Brown, Amy J. Johnson, John C. Byrd

    Publicat 2018
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  14. 14
    The role of phosphatidylinositol 3-kinase-δ in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia

    The role of phosphatidylinositol 3-kinase-δ in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia per Sarah E.M. Herman, Rosa Lapalombella, Amber Gordon, Asha Ramanunni, Kristie A. Blum, Jeffrey A. Jones, Xiaoli Zhang, Brian J. Lannutti, Kamal D. Puri, Natarajan Muthusamy, John C. Byrd, Amy J. Johnson

    Publicat 2011
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  15. 15
    Ibrutinib antagonizes rituximab-dependent NK cell–mediated cytotoxicity

    Ibrutinib antagonizes rituximab-dependent NK cell–mediated cytotoxicity per Holbrook E. Kohrt, Idit Sagiv-Barfi, Sarwish Rafiq, Sarah E.M. Herman, Jonathan P. Butchar, Carolyn Cheney, Xiaoli Zhang, Joseph J. Buggy, Natarajan Muthusamy, Ronald Levy, Amy J. Johnson, John C. Byrd

    Publicat 2014
    Obtenir text complet Obtenir text complet
    Carta
    Afegir a favorits
    Guardat en:
  16. 16
    Lymphocyte cytosolic protein 1 is a chronic lymphocytic leukemia membrane-associated antigen critical to niche homing

    Lymphocyte cytosolic protein 1 is a chronic lymphocytic leukemia membrane-associated antigen critical to niche homing per Jason A. Dubovsky, Danielle L. Chappell, Bonnie K. Harrington, Kitty Agrawal, Leslie A. Andritsos, Joseph M. Flynn, Jeffrey A. Jones, Michael E. Paulaitis, Brad Bolon, Amy J. Johnson, John C. Byrd, Natarajan Muthusamy

    Publicat 2013
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  17. 17
    <i>Retracted:</i> Antitumor effects of OSU‐2S, a nonimmunosuppressive analogue of FTY720, in hepatocellular carcinoma

    <i>Retracted:</i> Antitumor effects of OSU‐2S, a nonimmunosuppressive analogue of FTY720, in hepatocellular carcinoma per Hany A. Omar, Chih-Chien Chou, Lisa D. Berman-Booty, Yihui Ma, Jui‐Hsiang Hung, Dasheng Wang, Takayuki Kogure, Tushar Patel, Luigi Terracciano, Natarajan Muthusamy, John C. Byrd, Samuel K. Kulp, Ching‐Shih Chen

    Publicat 2011
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  18. 18
    Interleukin-10 suppression enhances T-cell antitumor immunity and responses to checkpoint blockade in chronic lymphocytic leukemia

    Interleukin-10 suppression enhances T-cell antitumor immunity and responses to checkpoint blockade in chronic lymphocytic leukemia per Jacqueline R. Rivas, Y Liu, Sara S. Alhakeem, Joseph M. Eckenrode, Francesc Martí, James P. Collard, Yanbin Zhang, Khaled A. Shaaban, Natarajan Muthusamy, Gerhard Hildebrandt, Roger A. Fleischman, L Chen, Jon S. Thorson, Markos Leggas, Subbarao Bondada

    Publicat 2021
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  19. 19
    Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical

    Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical per Zhao Xiaobin, Rosa Lapalombella, Trupti Joshi, Carolyn Cheney, Aruna Gowda, Martha Hayden-Ledbetter, Peter Baum, Thomas S. Lin, David Jarjoura, Amy Lehman, Donna Kussewitt, Robert J. Lee, Michael A. Caligiuri, Susheela Tridandapani, Natarajan Muthusamy, John C. Byrd

    Publicat 2007
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  20. 20
    IL-21 mediates apoptosis through up-regulation of the BH3 family member BIM and enhances both direct and antibody-dependent cellular cytotoxicity in primary chronic lymphocytic leukemia cells in vitro

    IL-21 mediates apoptosis through up-regulation of the BH3 family member BIM and enhances both direct and antibody-dependent cellular cytotoxicity in primary chronic lymphocytic leu... per Aruna Gowda, Julie M. Roda, Syed-Rehan A. Hussain, Asha Ramanunni, Trupti Joshi, S. Schmidt, Xiaoli Zhang, Amy Lehman, David Jarjoura, William E. Carson, Wayne Kindsvogel, Carolyn Cheney, Michael A. Caligiuri, Susheela Tridandapani, Natarajan Muthusamy, John C. Byrd

    Publicat 2008
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:

Eines de cerca: